Back

Effect of beta-blockers on mortality in heart failure with mid-range and preserved ejection fraction: a meta-analysis

31 August 2019 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster Session 4 - Heart failure treatment, HFpEF, HFmrEF Heart Failure with Preserved Ejection Fraction (HFpEF) ESC Premium Access ESC Congress 2019

About the speaker

Photo
Associate Professor Hidekatsu Fukuta

Nagoya City University Graduate School of Medical Sciences, Nagoya (Japan)

9 More presentations in this session

Presentation thumbnail
Comparative efficacy of renin-angiotensin aldosteron system modulators and angiotensin receptor neprilyzin inhibitor in chronic heart failure with reduced, mid-ranged and preserved ejection fraction
Professor L. Tumasyan (Yerevan, AM)
Abstract Slides
Presentation thumbnail
The predictive value of global longitudinal strain in patients with heart failure mid-range ejection fraction
Doctor C. Wei-Ting (Tainan, TW)
Abstract Slides
Presentation thumbnail
Change in left ventricular ejection fraction and outcome in heart failure patients with mid-range ejection fraction: from the HIJ-HF prospective study
Doctor K. Tsukamoto (Tokyo, JP)
Abstract
Presentation thumbnail
Natriuretic peptides added to clinical parameters predict two-year prognosis of patients with chronic heart with mid-range and reduced ejection fraction.
Professor J. Spinar (Brno, CZ)
Abstract Slides
Presentation thumbnail
Rehospitalization burden in heart failure with mid-range ejection fraction and morbidity burden. Is it a distinct phenotype?
Doctor E. Santas Olmeda (Valencia, ES)
Abstract

Access the full session

Session thumbnail
Poster Session 4 - Heart failure treatment, HFpEF, HFmrEF

The Event

Event poster

ESC Congress 2019

31 August - 4 September 2019
You may be interested in
thumbnail
Congress Presentation
Distinguishing heart failure with reduced ejection fraction from heart failure with preserved ejection fraction: a phenomics approach.
thumbnail
Congress Presentation
Pharmacotherapy in HFpEF: where do cardiometabolic drugs fit in?
thumbnail
Congress Session
Clinical phenotypes of heart failure with preserved ejection fraction

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources